Study guide
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories
Key Takeaways Explain This Topic AI
Uterine activity quantification requires evaluating contraction frequency, duration, intensity, and resting tone; uterine tachysystole is strictly defined as >5 contractions in 10 minutes averaged over a 30-minute window, with or without associated fetal heart rate decelerations.
Baseline fetal heart rate is normally 110–160 bpm; baseline variability reflects the dynamic balance between sympathetic and parasympathetic autonomic inputs, with moderate variability (6–25 bpm) serving as the single most reliable clinical indicator of an intact fetal central nervous system and absence of severe metabolic acidemia.
Fetal heart rate decelerations reflect distinct pathophysiological mechanisms: early decelerations stem from vagal stimulation due to transient fetal head compression (benign); late decelerations reflect uteroplacental insufficiency and transient fetal hypoxemia; variable decelerations indicate umbilical cord compression; and a sinusoidal pattern indicates critical fetal anemia or severe fetomaternal hemorrhage.
The NICHD Three-Tier FHR Interpretation System stratifies tracings into Category I (normal, strongly predictive of normal fetal acid-base status), Category II (indeterminate, requiring continuous surveillance, intrauterine resuscitation, and reevaluation), and Category III (abnormal acid-base status, requiring immediate intrauterine resuscitation and prompt delivery if uncorrected).
Evidence-based intrauterine resuscitation protocols employ a rapid multi-step bundle: lateral maternal repositioning to alleviate aortocaval compression, rapid intravenous crystalloid fluid bolus (500–1000 mL), supplemental oxygen only for documented maternal hypoxemia, discontinuation of uterotonics, administration of subcutaneous terbutaline (0.25 mg) for tachysystole, and amnioinfusion for recurrent variable decelerations.
Last updated: October 2026
Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories
Intrapartum electronic fetal monitoring (EFM) evaluates fetal oxygenation and acid-base status during labor. The goal is to detect progressive fetal hypoxemia and acidemia early, enabling interventions that prevent hypoxic-ischemic encephalopathy (HIE) or demise while avoiding unnecessary operative delivery.
Surveillance Modalities & Uterine Activity Assessment
Surveillance modalities include intermittent auscultation (IA) via Doppler or Pinard stethoscope (for low-risk pregnancies: every 15–30 min in active first stage, every 5–15 min in second stage) and continuous EFM. Continuous monitoring combines an external ultrasound transducer with a tocodynamometer. When external tracings are unreliable, internal options include the fetal spiral electrode (FSE) (direct R-wave tracking; contraindicated in maternal HIV, hepatitis B/C, active genital HSV, or fetal coagulopathy) and the intrauterine pressure catheter (IUPC) , which quantifies contractions in millimeters of mercury (mm Hg) and calculates Montevideo Units (MVUs) .
Uterine activity assessment measures contraction frequency, duration, intensity, and resting tone (normal: 8–15 mm Hg):
Normal Uterine Activity: <=5 contractions in 10 minutes, averaged over 30 minutes.
Uterine Tachysystole: >5 contractions in 10 minutes averaged over 30 minutes , with or without fetal heart rate (FHR) decelerations. Excessive contraction frequency restricts intervillous blood flow, depleting fetal oxygen reserves and leading to metabolic acidemia.
Important
Historical terms like "hyperstimulation" and "hypertonus" are obsolete. Clinicians must use uterine tachysystole , qualifying it by etiology (spontaneous vs. induced) and presence of decelerations.
FHR Baseline, Variability & Accelerations
Standardized NICHD definitions guide the interpretation of fetal heart rate patterns:
Baseline FHR: Mean heart rate rounded to 5 bpm increments over 10 minutes (excluding periodic changes and marked variability; must be present for >=2 minutes). Normal range is 110 to 160 bpm .
Tachycardia (>160 bpm for >=10 min): Caused by maternal intraamniotic infection/chorioamnionitis, maternal fever, medications (terbutaline, atropine), illicit stimulants, or early compensatory hypoxemia.
Bradycardia (<110 bpm for >=10 min): Caused by maternal hypotension (post-epidural), cord prolapse, rapid descent, congenital complete heart block (anti-Ro/SSA antibodies), or terminal acidemia.
Baseline Variability: Fluctuations in baseline FHR, reflecting autonomic sympathetic-parasympathetic interplay:
Absent: Undetectable amplitude; indicates severe metabolic acidemia or structural injury.
Minimal (<=5 bpm): Caused by fetal sleep cycles (typically 20–40 min), CNS depressants (opioids, magnesium sulfate), prematurity, or developing acidemia.
Moderate (6 to 25 bpm): Gold standard indicator of an intact, oxygenated central nervous system; reliably rules out fetal metabolic acidemia.
Marked (>25 bpm): Often an acute compensatory response to transient stress or acute cord compression.
Accelerations: Abrupt increase in FHR (onset to peak <30 sec). At >=32 weeks , peak >=15 bpm above baseline lasting >=15 seconds. At <32 weeks , peak >=10 bpm lasting >=10 seconds. Spontaneous or stimulated accelerations reliably indicate a cord arterial pH >7.20.
Decelerations & Pattern Morphology
Deceleration Type Timing & Morphology Pathophysiologic Mechanism Clinical Significance & Action
Early Deceleration Gradual decrease (onset to nadir >=30 sec) symmetrically mirroring the contraction; nadir matches contraction peak. Fetal head compression stimulating vagal parasympathetic discharge. Benign physiologic event. No hypoxemia or acidemia; expectant management without intervention.
Late Deceleration Gradual decrease (onset to nadir >=30 sec) with onset, nadir, and recovery occurring after contraction onset, peak, and end. Uteroplacental insufficiency with transient fetal hypoxemia below critical PaO2 (<15–18 mm Hg). Non-reassuring pathologic sign. Indicates fetal hypoxia; requires immediate intrauterine resuscitation.
Variable Deceleration Abrupt drop (onset to nadir <30 sec) >=15 bpm lasting >=15 sec but <2 min; sharp V-shape with preceding/following "shoulders." Umbilical cord compression causing increased afterload and baroreceptor-mediated vagal slowing. Common in labor. Atypical features (loss of variability, slow recovery) portend acidemia. Treat with repositioning/amnioinfusion.
Prolonged Deceleration Decrease in FHR >=15 bpm lasting >=2 minutes but <10 minutes . Sustained oxygenation disruption (cord prolapse, tachysystole, maternal hypotension, abruption). Emergent clinical crisis. If >=10 minutes, classified as bradycardia, requiring rapid delivery if unresolved.
Sinusoidal Pattern Smooth, undulating sine wave (3–5 cycles/min) lasting >=20 minutes , devoid of accelerations. Severe fetal anemia , fetomaternal hemorrhage, Rh alloimmunization, or twin-to-twin transfusion. Category III pattern. Severe compromise requiring immediate delivery or intrauterine blood transfusion.
NICHD Three-Tier Interpretation System
Category I (Normal): Requires baseline 110–160 bpm, moderate variability, absence of late/variable decelerations, early decelerations present or absent, and accelerations present or absent. Strongly predictive of normal fetal acid-base status; manage expectantly.
Category II (Indeterminate): All tracings not meeting Category I or III (e.g., minimal variability, marked variability, absent accelerations, recurrent variable decelerations with moderate variability, prolonged decelerations). Not predictive of abnormal acid-base status; mandates continuous monitoring, intrauterine resuscitation, and reevaluation.
Category III (Abnormal): Demonstrates absent baseline variability PLUS recurrent late decelerations, recurrent variable decelerations, or bradycardia; OR a sinusoidal pattern . Predictive of abnormal acid-base status; requires prompt resuscitation and emergent delivery if uncorrected.
Algorithmic Intrauterine Resuscitation Protocol
When intrauterine resuscitation is indicated, implement the following bundle:
Maternal Repositioning: Turn patient to left lateral (or right lateral / hands-and-knees) to relieve aortocaval compression and alleviate cord compression.
IV Fluid Bolus: Rapid infusion of 500 to 1,000 mL crystalloid (lactated Ringer's) to expand intravascular volume and enhance uteroplacental perfusion.
Discontinue Uterotonics: Stop oxytocin infusions or remove dinoprostone inserts to resolve tachysystole.
Administer Tocolytics: Give terbutaline 0.25 mg subcutaneously if tachysystole and decelerations persist.
Supplemental Oxygen: Administer 8–10 L/min via non-rebreather mask only if maternal SpO2 <95% ; routine O2 in normoxic gravidas offers no fetal benefit.
Vaginal Examination: Palpate for rapid descent or prolapsed umbilical cord.
Amnioinfusion: Infuse warm normal saline via IUPC for recurrent variable decelerations to cushion the cord.